Updates

Axon regularly acts as a sub-contractor for leading international firms to assist in regulatory due diligence in our fields of expertise: pharma, medical technology and food.

Axon assisted a French VC company investing in a food tech start-up. We reviewed the target’s regulatory strategy under the EU novel foods framework, assessed its feasibility and outlined potential risks and how to mitigate these.

We have advised several clients, including Dutch Growth Funds, on the structuring and application of government funding and related public-private partnership schemes aimed at stimulating innovation in the life sciences and health sector. Our advice covers the design and structuring of funding schemes, including the formulation of eligibility criteria and subsidy conditions, the establishment of governance frameworks for public-private consortia, and the administrative and legal requirements for the disbursement of government-funded research and development grants.

Our team has trained several multinationals on the implications of the Battery Regulation and the Packaging & Packaging Waste regulation, and regularly advises on these topics.

We have advised a mid-size company on extended producer responsibilities under environmental legislation.

We have advised a Dutch packaging manufacturer on the use of colours, inks and substances in food packaging and have prepared a fact sheet on environmental claims for a client focussed on sustainable packaging.

Our sustainability team has assisted a client in drafting a sustainability code of conduct.

Axon regularly provides specialist due diligence support on a variety of corporate transactions in the life sciences sector.

We have conducted regulatory due diligence on behalf of a private equity firm in connection with the acquisition of a medical device manufacturer, covering MDR compliance (including notified body certificates and post-market surveillance obligations), as well as data protection aspects.

We have conducted regulatory due diligence in connection with the acquisition of a pharmacy, covering compliance with applicable pharmaceutical and healthcare legislation.